MA46563A - Compositions dispersibles - Google Patents

Compositions dispersibles

Info

Publication number
MA46563A
MA46563A MA046563A MA46563A MA46563A MA 46563 A MA46563 A MA 46563A MA 046563 A MA046563 A MA 046563A MA 46563 A MA46563 A MA 46563A MA 46563 A MA46563 A MA 46563A
Authority
MA
Morocco
Prior art keywords
dispersible compositions
dispersible
compositions
Prior art date
Application number
MA046563A
Other languages
English (en)
Other versions
MA46563B1 (fr
Inventor
Nicolaas Martha Felix Goyvaerts
Harshad Patankar
Rajan Gopal Rajan Ranga
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA46563A publication Critical patent/MA46563A/fr
Publication of MA46563B1 publication Critical patent/MA46563B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
MA46563A 2016-10-24 2017-10-23 Compositions dispersibles MA46563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (fr) 2016-10-24 2017-10-23 Compositions dispersibles

Publications (2)

Publication Number Publication Date
MA46563A true MA46563A (fr) 2019-08-28
MA46563B1 MA46563B1 (fr) 2024-01-31

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46563A MA46563B1 (fr) 2016-10-24 2017-10-23 Compositions dispersibles

Country Status (21)

Country Link
US (2) US11065198B2 (fr)
EP (2) EP4248947A3 (fr)
JP (2) JP7197474B2 (fr)
KR (2) KR20190073450A (fr)
CN (1) CN110191704A (fr)
CA (1) CA3039562A1 (fr)
DK (1) DK3528791T3 (fr)
ES (1) ES2970870T3 (fr)
FI (1) FI3528791T3 (fr)
HR (1) HRP20240118T1 (fr)
HU (1) HUE064823T2 (fr)
LT (1) LT3528791T (fr)
MA (1) MA46563B1 (fr)
MX (1) MX2019004767A (fr)
PL (1) PL3528791T3 (fr)
PT (1) PT3528791T (fr)
RS (1) RS65159B1 (fr)
SI (1) SI3528791T1 (fr)
SM (1) SMT202400060T1 (fr)
TW (1) TWI821163B (fr)
WO (1) WO2018077815A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
EP4065121A4 (fr) 2019-11-29 2023-11-29 Aptorum Therapeutics Limited Composition comprenant de la rilpivirine et son utilisation pour le traitement de tumeurs ou du cancer
WO2021253380A1 (fr) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Formulations orales et leurs utilisations
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (fr) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Comprimés dispersibles enrobés par compression
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DK1529032T3 (da) 2002-08-09 2013-07-08 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill
AU2005279158C1 (en) * 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
BRPI0514871A (pt) * 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
CN101478950B (zh) 2006-06-23 2013-02-06 泰博特克药品有限公司 Tmc278的水性悬浮液
WO2015120014A1 (fr) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Nouveaux systèmes de désintégration de formes dosifiées pharmaceutiques
WO2015136294A1 (fr) * 2014-03-13 2015-09-17 Cipla Limited Composition pharmaceutique comprenant de la rilpivirine
EP3142640A1 (fr) * 2014-05-16 2017-03-22 Vivus, Inc. Forme dosifiée à désintégration par voie orale pour l'administration d'avanafil, et procédés associés de fabrication et d'utilisation

Also Published As

Publication number Publication date
JP2020500168A (ja) 2020-01-09
SI3528791T1 (sl) 2024-04-30
KR102861006B1 (ko) 2025-09-16
EP3528791B1 (fr) 2023-12-06
PL3528791T3 (pl) 2024-04-02
BR112019007564A2 (pt) 2019-07-02
RU2019115672A (ru) 2020-11-24
RU2019115672A3 (fr) 2021-01-21
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30
JP2023011659A (ja) 2023-01-24
PT3528791T (pt) 2024-02-19
SMT202400060T1 (it) 2024-03-13
TWI821163B (zh) 2023-11-11
HUE064823T2 (hu) 2024-04-28
ES2970870T3 (es) 2024-05-31
CA3039562A1 (fr) 2018-05-03
WO2018077815A1 (fr) 2018-05-03
RS65159B1 (sr) 2024-02-29
HRP20240118T1 (hr) 2024-04-12
LT3528791T (lt) 2024-05-27
EP4248947A3 (fr) 2023-11-22
US20200069579A1 (en) 2020-03-05
MA46563B1 (fr) 2024-01-31
JP7197474B2 (ja) 2022-12-27
KR20190073450A (ko) 2019-06-26
DK3528791T3 (da) 2024-01-29
EP4248947A2 (fr) 2023-09-27
EP3528791A1 (fr) 2019-08-28
TW201828927A (zh) 2018-08-16
MX2019004767A (es) 2019-07-01
US11065198B2 (en) 2021-07-20
CN110191704A (zh) 2019-08-30
US20220008333A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
EP3534968A4 (fr) Compositions de lymphocytes t car anti-bcma
MA46458A (fr) Compositions debacillus thuringiensis
DK3361870T3 (da) Fungicidsammensætninger
EP3493800A4 (fr) Composition decannabis
MA41411A (fr) Compositions dispersibles
DK3416996T3 (da) Hærdelig sammensætning
DK3215173T3 (da) Glycopeptidsammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3528902T3 (da) Ringegelsammensætning
PT3261437T (pt) Compostos e composições fungicidas
EP3430073A4 (fr) Composition de polyaryléthercétone
DK4234656T3 (da) Sammensætninger
EP3458041A4 (fr) Compositions antibactériennes
DK3322295T3 (da) Sammensætning
EP3480228A4 (fr) Composition
DK3316857T3 (da) Multifasiske sammensætninger
MA46563A (fr) Compositions dispersibles
DK3317458T3 (da) Mineralsammensætninger
EP3556804A4 (fr) Composition
EP3478296A4 (fr) Compositions de phosopholipides
EP3524627A4 (fr) Composition
EP3443034C0 (fr) Composition
DK3416502T3 (da) Glykæmisk-reducerende sammensætning
BR112017016240A2 (pt) composição
DK3200827T3 (da) Sammensætninger